J. Castillo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
J. Castillo has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
A. Sampera
Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), Doctor Aiguader, 88, 08003, Barcelona
1 shared publication- Ana Rovira
Cancer Research Program, IMIM (Hospital del Mar Research Institute), 08003 Barcelona, Spain
1 shared publication - Andrés Cervantes
INCLIVA Biomedical Research Institute, 46010 Valencia, Spain
1 shared publication - Clara Montagut
Hospital del Mar Research Institute Barcelona, Medical Oncology Department, Hospital del Mar, Barcelona, Spain; Universitat Pompeu Fabra, Barcelona, Spain; Centro de Investigación Biomédica en Red de Oncología (CIBERONC-ISCIII), Madrid, Spain
1 shared publication D. Roda
INCLIVA Health Research Institute, Hospital Clinico Universitario de Valencia, avenida Menendez y Pelayo 4, 46010, Valencia
1 shared publication- Francisco Gimeno-Valiente
Cancer Evolution and Genome Instability Laboratory, University College London Cancer Institute, London, UK
1 shared publication
Latest Publications
- Open Access
- 13 October 2017
- Published by Elsevier in Annals of Oncology
- Vol. 28 (suppl_7) , vii16
SRC-S6 axis as a potential mechanism of resistance to anti HER2 treatment in gastric cancer (GC) cell lines
Background: HER2 receptor amplification or overexpression represents an important driver in 7-34% of cases of GC, playing a relevant role in cell growth, survival and differentiation. In HER2 positive GC, trastuzumab, a humanized antibody against HER2, when combined with 5FU/capecitabine and cisplatin, improves median overall survival. Nevertheless, primary and acquired resistance to the treatment eventually develops.
- 13 October 2017
- Published by Elsevier in Annals of Oncology
- Vol. 28 (suppl_7) , vii16
Open AccessSRC-S6 axis as a potential mechanism of resistance to anti HER2 treatment in gastric cancer (GC) cell lines
Background: HER2 receptor amplification or overexpression represents an important driver in 7-34% of cases of GC, playing a relevant role in cell growth, survival and differentiation. In HER2 positive GC, trastuzumab, a humanized antibody against HER2, when combined with 5FU/capecitabine and cisplatin, improves median overall survival. Nevertheless, primary and acquired resistance to the treatment eventually develops.